Vectura Group said today it has halted development of its asthma drug-device combination VR475 following its failure in a Phase III European trial. VR475 consists of a budesonide inhalation suspension ...
Satsuma Pharmaceuticals has presented phase 1 data on its second-generation nasal delivery device. The readout positions Satsuma to start a phase 3 clinical trial designed to enable it to bounce back ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback